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Abstract
Background: Due to an improving prognosis, and increased knowledge of intervention effects over time, long-
term well-being among prostate cancer (PC) survivors has gained increasing attention. Yet, despite a variety of
available PC interventions, experts currently disagree on optimal intervention course based on survival rates.
Methods: In January 2017, we searched multiple databases to identify relevant articles. Studies were required to
assess at least two different dimensions of health-related quality of life (HRQoL) in PC survivors ≥5 years past
diagnosis with validated measures.
Results: Identified studies (n = 13) were mainly observational cohort studies (n = 10), conducted in developed
countries with a sample size below 100 per study arm (n = 6). External-beam radiation therapy was the most
common intervention (n = 12), whereas only three studies included patients on active surveillance or on watchful
waiting.
Studies were largely heterogeneous in cancer stage at diagnosis, intervention groups and instruments. All identified
studies either used the EORTC QLQ-C30 (n = 5) or the SF-36 (n = 7) to assess generic HRQoL, yet 11 different
instruments were employed to assess PC specific urinary, bowel and sexual symptoms. Overall, no consistent
pattern between intervention and HRQoL was observed. Results from two randomized-controlled-trials (RCTs) and
one observational study, comparing HRQoL by primary intervention in localized PC survivors suggest that long-term
HRQoL does not differ by intervention. However, observational studies that included a combination of localized and
locally advanced stage PC survivors identified HRQoL differences for various scales including physical well-being,
social and role function, vitality, and role emotional.
Conclusion: This review reveals the number of publications comparing HRQoL by primary intervention in long-
term PC survivors is currently limited. Robust data from two RCTs and one observational study suggest that HRQoL
does not seem to differ by intervention. However, the heterogeneity of studies’ methodologies and results
hindered our ability to draw a clear conclusion. Therefore, in order to answer the question of which primary
intervention is superior with respect to long-term HRQoL in PC patients, more high-quality, large-scale prospective
cohort studies, or RCTs with repeated HRQoL assessments, are urgently needed.
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Background
In economically developed countries, prostate cancer
(PC) continues to be the most frequent cancer in men
[1]. In Europe, for example, approximately 400,000 men
are diagnosed with PC annually [2]. Patient prognosis
has substantially improved due to earlier diagnosis and
advancements in therapy, leading to five-year relative
survival rates of 99.1% (2008) in the US [3] and 93% in
Europe [4]. Consequently, the number of PC survivors is
on the rise [5]. In particular, the number of long-term
survivors (i.e. those still alive 5 years after initial diagno-
sis [6]) is substantially increasing.
A variety of intervention options, including radical pros-
tatectomy (RP), radiotherapy (external beam (EBRT) or
brachytherapy (BT)), chemotherapy (CT), cyberknife (CK),
cryotherapy (CRYO), androgen deprivation therapy (ADT),
active surveillance (AS) and watchful waiting (WW)) are
now available. [7–10] However, there is currently no agree-
ment on the optimal intervention, based on survival rates,
especially for men with localized stage PC [8, 9, 11].
Despite increased awareness regarding long-term
outcomes and patient-reported outcomes (including
health-related quality of life (HRQoL)), a gold-standard
definition of HRQoL does not currently exist. However,
researchers agree that HRQoL is a multidimensional
concept that encompasses all aspects of survivors’ well--
being including physical, psychological, social and spirit-
ual health [12, 13]. Additionally, global HRQoL (or
overall health perceptions) must be added to this multi-
dimensional concept, as it has proven to be an import-
ant predictor of individuals’ health [14].
Although HRQoL outcomes are useful to define the
harmful and beneficial effects of interventions from the pa-
tient’s perspective, differences in HRQoL outcomes of long-
term PC survivors (≥ 5 years since diagnosis) [15] between
interventions have rarely been documented [16, 17]. Due to
high PC survival rates and low PC-specific mortality rates
(which do not differ between interventions [8, 18]),
information on long-term HRQoL should be analyzed and
subsequently considered as an additional factor in interven-
tion decisions. HRQoL is especially relevant because other
measurements (e.g. survival/mortality rates) do not cur-
rently indicate superiority of one intervention over the
others [11, 19–21].
This systematic review aims to identify all studies asses-
sing HRQoL among long-term PC survivors by primary
intervention. Findings will be synthesized and critically
discussed with respect to study design and methodology.
Method
We followed the standard systematic review methodology
outlined by the Centre for Reviews and Dissemination (York,
UK) [22] and the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) group [23].
Study eligibility criteria
This systematic review includes all quantitative com-
parative studies on PC survivors diagnosed a mini-
mum of 5 years prior to HRQoL assessment. When
studies also included short- or medium-term survi-
vors, it was critical the researchers of these studies
examined results specifically pertaining to long-term
PC survivors.
At minimum, study outcomes had to report on overall/
general HRQoL plus one HRQoL domain, or at least two
HRQoL domains. Domains were defined as physical, psy-
chological, social and spiritual well-being [12, 24]. Only
validated assessment instruments were included, such as
the European Organization for Research and Treatment
of Cancer Core Questionnaire (EORTC QLQ-C30) [25],
the 36-item Short Form Health Survey (SF-36) [26] or the
Functional Assessment of Cancer Therapy - General
(FACT-G) [27]. Further, we required HRQoL results to be
explicitly reported by type of primary intervention. Inter-
ventions could be either RP, EBRT, BT, ADT, CT, CK,
CRYO, AS or WW, as well as, combinations of these in-
terventions. It was necessary each study compared the
HRQoL of different interventions, or one intervention to
the HRQoL of a reference group (e.g. general population).
Without an available gold-standard classification of inter-
vention options (e.g. active surveillance), all intervention
options are classified as “intervention,” for our purposes
[28–30]. Moreover, researchers had to report on informa-
tion regarding age and date of diagnosis and time post
diagnosis. All included articles were published in English,
German, French or Italian.
Search strategy and study selection
The literature search was completed in January 2017 using
the following electronic databases: Pubmed, Medline,
Embase, PsychInfo, Cinahl, Web of Science and Cochrane
Central Register of Controlled Trials. Additionally, we
hand-searched the bibliographies of reviews, conference
proceedings, and supplements to identify further relevant
studies. Authors of these publications were contacted for
further details.
The following combinations were used: “quality of life,
HRQoL, patient satisfaction, well-being, general health sta-
tus assessment, qlq c30, pr 25, sf 36” AND “cancer survivor,
long-term, year after” AND “prostate cancer, prostate
adenocarcinoma, prostate neoplasm, prostate neoplasia,
prostate carcinoma” (Additional file 1: Appendix A).
One author (SaA) assessed eligibility and selected the
articles by screening records based on title/abstract re-
view. Further, two reviewers (SaA and AF) assessed the
full-texts according to predefined, hierarchically ordered
inclusion and exclusion criteria. In the case of doubt, a
third reviewer (VA) made the final decision. The flow
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diagram of the search and selection process is outlined
in Fig. 1.
Data extraction and quality assessment
Data were independently extracted by two reviewers (SaA,
AF) using a systematic scheme containing the following
study characteristics: title, first author, year, country, study
design, age range, cancer stage, intervention(s), comorbid-
ities, response rate, time since diagnosis/randomization,
HRQoL instrument(s), statistical methods and results.
Only data pertaining to long-term survivors was extracted.
Reviewers described study results and indicated whether
they were statistically significant and/or clinically mean-
ingful [31–33]. The same reviewers assessed the methodo-
logical quality of each article, following the risk of bias
(RoB) criteria based on the GRADE approach [34], with
the following additional criteria: adjustment for attrition
error, sample size power, control for confounding, report-
ing of results appropriate (plots/diagrams/tables printed
sufficiently, lack of selective reporting of results), statistical
significance test(s) performed and baseline data available.
Results
Literature search results
Two thousand sixty articles were identified through the litera-
ture search. After removing duplicates, 1236 articles remained.
Screening of titles and abstracts identified 94 potentially eli-
gible articles (Figure 1). Full-text analyses identified 13 articles,
which were included in data extraction [35–47].
Study characteristics
Studies were exclusively conducted in developed countries:
seven in Europe [35, 37–39, 41, 43, 47], three in Japan [44–
46], two in the US [40, 42] and one completed in the US
and Europe [36] (Table 1). The majority were observational
prospective cohort studies (n = 7) [35, 38, 40, 42, 44–46],
three were observational retrospective cohort studies [39,
43, 47] and three were randomized controlled trials (RCTs)
[36, 37, 41] (Tables 1 and 2).
Fig. 1 Flow diagram of the search and selection process
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Recruitment of survivors
Recruitment was monocentric hospital-based in nine
studies [35, 38–42, 44–46], multicentric hospital-based
in one study [36] and population-based in three stud-
ies [37, 43, 47]. In ten studies, survivors were diag-
nosed with PC, on average (mean, median), five to 10
years before the time of HRQoL assessment. [36–40,
43–47] In three studies, survivors were diagnosed
more than 10 years before the time of HRQoL assess-
ment. [35, 41, 42] Most studies included long-term
PC survivors with localized (TNM stage: T1 & T2)
and locally advanced (TNM stage: T3 & T4) PC [35,
38, 39, 42, 43, 45, 46] (categorization based on [48,
49]). Whereas two studies specifically recruited survi-
vors after locally advanced PC [36, 44], four studies
recruited survivors after only localized PC. [37, 39,
41, 47]. Ten studies [35–41, 45–47] provided no in-
formation on how they analyzed recurrent PC cancer
survivors and whether recurrent PC cases were in-
cluded in their dataset. Two studies [42, 43] included
recurrent cancer patients and one excluded them, as
they died during the follow-up time [44].
The average age of PC survivors at HRQoL assessment
was around 75 years, ranging from 53 to 90 years of age.
The RCTs, and some prospective cohort studies, only re-
ported age at study enrollment (baseline). Thus, for
these studies, the study population age at different
HRQoL assessment time points can only be estimated.
One study excluded survivors with comorbid condi-
tions [35], whereas four [43–45, 47] studies explicitly
considered long-term PC survivors with comorbidities.
These studies showed that >60% of long-term PC survi-
vors were diagnosed with at least one comorbid
condition.
Participation rate and number of participants
Sample size was defined at time of HRQoL assess-
ment. Half of the studies had a sample size below
100 participants [35, 38, 39, 42, 45, 46], five had a
sample size between 101 and 200 participants [36,
40, 41, 44, 47], one had 780 participants [43] and
one study cohort consisted of 1463 participants 5
years post-randomization, with 1413 participants
remaining for analysis 6 years post-randomization
[37]. Participation rate (defined as the number of
participants divided by the number of eligible pa-
tients at the time of long-term HRQoL assessment)
was over 90% in one study [46], between 70 and
90% in ten studies [35–37, 39–45] and below 60% in
one study [47].
Intervention comparisons and stage at diagnosis
Interventions were generally classified as RP, EBRT (re-
ferring to the external delivery of any type of radiation),
ADT, BT, WW or AS. Studies either compared HRQoL
by primary intervention in long-term survivors with:
Table 2 Summary table of study characteristics
Characteristic Frequency
Study Design Randomized controlled trial
Observational prospective
cohort study
Observational retrospective
cohort study
3
7
3
Recruitment Monocentric hospital-based
Multicentral hospital-based
Population-based
9
1
3
Comparison: intervention vs. general
populationa
RP EBRT ADT WW AS
X 2
Xb 5
X 1
X 1
X 1
Comparison: intervention vs.
interventiona
RP EBRT ADT WW AS
X X X 1
X Xd 1
X X 1
X vs. Xc 1
Xc X 1
X X 1
X X 1
X X X X 1
X Xe X 1
X Xf 1
Sample sizes (total
population)
<100
101 – 200
780
1463 (after 5 years since
randomization) respectively
1413 participants (6 years
since randomization)
6
5
1
1
Years since diagnosis/
randomization
Long-term survivors (5-10 years
after diagnosis)
Very long-term survivors (10 +
years after diagnosis)
10
3
Stage at diagnosis Localized (T1/T2) PC
Locally advanced (T3/T4 any
N1/M1) PC
Localized & locally advanced
PC
No information
3
2
7
1
Recurrent PC survivors No information
Excluded
Included
10
1g
2
Progressive PC survivors No information
Excluded
Included
5
3
5
aSome studies had multiple comparisons
b“Plus ADT and/or clinical progression”
cPlus ADT
dBrachytherapy
eEBRT-C — Conventional radiation; EBRT-HD — High-dose mixed-beam
radiation; EBRT-LD — Low-dose mixed-beam radiation; EBRT-MB — Standard
protocol/mixed-beam radiation; EBRT-PB — Proton beam radiation
fBrachytherapy
gExcluded because they died
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S1) localized PC only [37, 41, 47],
S2) locally advanced PC only, [36, 44] or
S3) localized or locally advanced PC [35, 38, 39, 42, 43,
45, 46] (Tables 4 and 5).
Unfortunately, one study did not reveal information
about the cancer stage. This study was categorized as
stage X [40] (Tables 4 and 5).
Additionally, alternative comparison methods for
HRQoL among primary intervention groups were identi-
fied. Studies either compared:
T1) HRQoL of PC survivors undergoing a specific
primary intervention with controls from the general
population at certain points over time [35, 38, 42,
45, 47],
T2) HRQoL of PC survivors undergoing different
interventions to each other at certain time points
[36–41, 43, 46, 47] or.
T3) HRQoL of PC survivors undergoing different
interventions over a certain time period [36, 37, 44]
(Tables 1 and 3).
Overall, EBRT was the most commonly evaluated
intervention, followed by RP. The most common control
group was the general population (n = 10) [35, 38, 42–
44, 47] (Table 2).
Assessment of health-related quality of life and prostate
cancer specific symptoms
Included studies employed generic, as well as, disease-
specific HRQoL instruments.(Table 3) Seven studies
employed the SF-36 questionnaire as a generic HRQoL
assessment instrument [40, 42–47], and five studies used
the EORTC QLQ-C30 (Version 1.0 and 3.0) [35, 36, 38,
39, 41].
One study [37] used both the abbreviated form of
the SF-36, the SF-12, and the EORTC QLQ C30.
Additionally, two studies [43, 47] made use of the
Dutch version of the Quality of Life-Cancer Survivors
(QoL-CS) questionnaire [50]. The EORTC QLQ-C30
consists of five functional scales, nine symptom spe-
cific subscales and a global health status scale [25]. In
contrast, both the SF-36 and the SF-12 consist of
eight scales. The scales include general health percep-
tion, which encompasses two general domains: phys-
ical and mental well-being [26, 51]. Scales in both
instruments are linearly transformed to values from 0
to 100 [52]. In the EORTC QLQ-C30, a high score
for a functional scale represents a high/healthy level
of functioning, a high score for the global health sta-
tus/QoL represents a high QoL. Generally, a high
score for a symptom scale/item represents a high
level of symptomatology [52]. Most studies reported
statistically significant differences [36–41, 43–47]. Five
Table 3 Instruments
Instrument Abbreviation Frequency
Instruments to
assess HRQoL
European Organisation for Research and Treatment of Cancer Core
Questionnaire (30-items)
EORTC QLQ-C30 3
36-item Short Form Health Survey SF-36 7
12-item Short Form Health Survey & European Organisation for Research
and Treatment of Cancer Core Questionnaire (30-items)
SF-12 & EORTC QLQ-C30 1
European Organisation for Research and Treatment of Cancer Core
Questionnaire (30-items) & Quality of Life-Cancer Survivors questionnaire
EORTC QLQ-C30 & QoL-CS 2
Instruments to assess PC
symptoms
Brief Male Sexual Inventory & University of California Los Angeles
Prostate Cancer Index
BFSI & UCLA-PCI 1
European Organisation for Research and Treatment of Cancer Prostate
Cancer Specific Module (19 -items, pre-version of PR25)
EORTC QLQ-PR25/PR-19 1
Expanded Prostate Cancer Index & International Continence Society Male
Short-Form questionnaire & Hospital Anxiety and Depression Scale
EPIC & ICSaleSF & ICIQ & HADs 1
Southwest Oncology Group Treatment Specific Measure ‚—‘ 1
Prostate Cancer Symptom Scale PCSS 2
International Prostate Symptom Score & International Index of Erectile
Function
IPSS & IIEF 1
University of California Los Angeles Prostate Cancer Index UCLA-PCI 2
International Prostate Symptom Score & University of California Los Angeles
Prostate Cancer Index
IPSS & UCLA-PCI 1
University of California Los Angeles Prostate Cancer Index & Hospital Anxiety
and Depression Scale
UCLA-PCI & HADS 1
Expanded Prostate Cancer Index & Dutch Sexual Activities Module EPIC & SAc 1
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studies completed an additional analysis if the results
were clinically meaningful [35–37, 39, 43].
PC specific symptoms were assessed with 11 different
instruments. [53–63] (Table 3). Additionally, the
Hospital Anxiety and Depression Scale (HADS) [64] was
used in two studies. [37, 46] Six studies [37, 38, 40, 41,
45, 46] combined different instruments, six [35, 36, 39,
42, 44, 47] used one instrument, and one study did not
assess PC specific symptoms [43]. Scales of disease-
specific HRQoL instruments were mainly related to
urinary, bowel and sexual functions/problems.
Study findings
Overall, studies were heterogeneous and most had poten-
tial limitations. Therefore, we decided to systematically re-
port but not pool (e.g. in a meta-analysis), the main results.
Further, we divided the results between RCTs and observa-
tional studies and grouped them by disease stage. (Tables 4
and 5, Additional file 1: Appendix Tables B and C).
HRQoL by primary intervention in long-term survivors with
localized PC
Three studies assessed HRQoL in long-term survivors
with localized stage PC [37, 41, 47]. Comparisons were
drawn from two RCTs, comparing either AS vs. RP vs.
EBRT, or RP vs. EBRT [37, 41] and one observational
study comparing AS vs. EBRT. Both interventions used
controls from the general population [47].
These three studies showed that long-term survivors
with localized stage PC have comparable HRQoL inde-
pendent from the chosen intervention. (Tables 4 and 5)
Moreover, one study revealed that PC survivors do not
experience any reduction in their HRQoL, except for
deficits in physical function, when compared with con-
trols from the general population. [47] However, in two
studies [37, 47] EBRT had an effect on bowel function.
Additionally, one RCT reported that RP had the greatest
negative effect on urinary and sexual function, compared
to survivors on AS or survivors treated with EBRT [37]
(Additional file 1: Appendix Tables B and C).
HRQoL by primary intervention in long-term survivors with
locally advanced PC
Two studies (one RCT, one observational study) assessed
HRQoL in long-term survivors with locally advanced PC
[36, 44]. The RCT compared PC survivors treated with
ADT vs. ADT + EBRT [36] and the observational study
RP vs. EBRT [44]. Only the RCT reported results for
intervention comparisons at specific time points. In this
RCT, no difference in HRQoL or PC symptoms could be
identified. After 5 years, the observational study shows
both interventions have good outcomes, whereas PC pa-
tients treated with RP reported better well-being [36].
HRQoL by primary intervention in long-term survivors with
localized or locally advanced PC
Seven observational studies compared HRQoL in survi-
vors with localized and locally advanced stage PC [35,
38, 39, 42, 43, 45, 46]. In four studies [35, 38, 42, 43], PC
survivors treated with EBRT were compared with con-
trols from the general population, whereas in three [35,
42, 43] of these four studies, PC survivors were addition-
ally treated with ADT. In these four studies, no uniform
pattern in HRQoL differences could be identified. Three
Table 4 Main findings on HRQoL in RCTs
Comp.: Study Key Findings Potential Limitation(s)
S1a Donovan,
J L/
2016 [37]
Comparison: AS vs. RP vs. EBRT, follow-up timeb: 5-6 years, mean
agec: 62 years
- No significant differences were observed among intervention groups in
measures of general health-related or cancer-related quality of life
S1 Giberti, C/ 2009 [41] Comparison: RP vs. BT, follow-up timeb: 5 years, mean agec: 65.3
years
- No significant differences were observed among intervention groups
in measures of general health-related or cancer-related quality of life
- Sample size <100 in both study arms
- No intention to treat analyses
S2 Brundage, M/ 2015 [36] Comparison: ADT vs. ADT + EBRT, follow-up timeb: 5-8 years,
median agec: 69.7 years
- No significant between-arm differences in physical or role functioning
at any time point 5+ years after diagnosis
- Significant (p < 0.001) deterioration in both arms over time for physical
and role functioning
- Sample size <100 in both study arms
- Only results on physical and role
functioning were reported for this
follow-up time
Comp. Comparison group
S1: HRQoL by primary intervention in long-term survivors with localized PC; S2: HRQoL by intervention in long-term survivors with locally advanced PC; S3: HRQoL
by intervention in long-term survivors with localized or locally advanced PC
Studies were ordered by stage information and within each group alphabetically
As potential limitation following criteria were considered: (1) sample size 100 per study arm for studies using EORTC-C30 and 70 for studies using SF-36 (2)
randomization (3) intention to-treat analyses (4) reporting of results appropriate
aInlcusion of PC survivors with disease progression
bTime since randomization
cAge at randomization
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[35, 38, 42] studies reported significant, or even clinically
relevant, functioning in different HRQoL domains (so-
cial, role and emotional functioning) and a higher bur-
den of diarrhea, appetite loss, nausea, pain and
insomnia. Conversely, the fourth study [43] revealed that
patients reported comparable HRQoL, and less bodily
pain, in comparison to a control group from the general
population. However, for PC specific symptoms, authors
could identify more detriments in sexual function domains
(n = 2) [35, 42] and more urinary bowel problems (n = 2)
[38, 42] when compared to controls from the general
population (Tables 4 and 5, Additional file 1: Appendix
Tables B and C).
When PC survivors treated with EBRT were compared to
either PC survivors treated with RP or WW, no significant
results in HRQoL could be identified [39, 46]. The same re-
sult applies for the comparison of PC survivors treated with
RP vs. controls from the general population [45].
The one study comparing PC survivors treated with
RP vs. EBRT vs. ADT vs. WW showed significant differ-
ences were observed in physical functioning and physical
well-being, whereas survivors treated with RP had the
best scores in these domains. Further, survivors treated
with ADT had the lowest scores. In a separate analysis
comparing all the intervention groups with controls
from the general population, no intervention group re-
ported worse HRQoL [43].
Discussion
Five and 10 year PC-specific survival rates are nearing
100%, seemingly independent from type of primary
intervention [18]. Consequently, experts continue to dis-
agree on a preferred intervention course, particularly in
the disease’s early stages.
This review identified 13 studies (three RCTs and 10
observational studies), which evaluated HRQoL and PC
specific symptoms in long-term PC survivors at different
cancer stages. Studies varied in terms of intervention
comparison groups, instruments used, and whether/how
studies reported results on primary interventions for lo-
calized PC, locally advanced PC, or on both together
without distinction.
The main tested intervention group was EBRT (plus
ADT), and only limited information was available on PC
survivors treated with ADT only, and on PC survivors
on AS or WW. AS and WW are only recently consid-
ered standard care. Thus, the lack of studies in this re-
view focusing on long-term PC survivors (and two
earlier reviews including short-term survivors) undergo-
ing AS or WW, is not surprising [65, 66]. The limited
number of studies assessing HRQoL in PC survivors
treated with ADT is also logical, as ADT is mainly indi-
cated in patients with advanced stage PC, which has a
shorter survival time [67].
To assess generic HRQoL, studies either used the SF-
36, or EORTC QLQ-C30, thus allowing for comparisons
to be drawn across at least some domains. However, our
review reveals a diverse number of instruments
employed in assessing PC specific symptoms. UCLA-
PCI (n = 4) was the most commonly employed instru-
ment, followed by the EPIC (n = 2) and IPSS (n = 2). The
first two questionnaires (UCLA-PCI and EPIC) focus on
urinary, sexual and bowel symptoms, whereas the latter
(IPSS) evaluates only urinary symptoms. The studies in
this review: (1) focused on only one questionnaire, (2)
used different combinations of the questionnaires, or (3)
did not evaluate PC specific symptoms at all, making it
impossible to pool results across studies.
Interestingly, the RCTs evaluated in this systematic
review included either PC survivors with localized PC
[37, 41] or locally advanced PC [36], whereas only two
observational studies [44, 47] made this distinction.
Therefore, the results of these observational studies
should be interpreted carefully, because the choice of
intervention is dependent on stage at diagnosis [10].
In addition to the use of diverse instruments, the ma-
jority of reviewed studies had potential limitations.
These limitations prevented our ability to draw firm
conclusions on HRQoL’s dependency on primary
intervention in long-term PC survivors. First, only three
studies [37, 43, 47] had sufficient power to detect prede-
termined differences in scores between groups. For ex-
ample, to detect a difference of ten points with a power
of 80% and alpha = 0.05, a sample size of 100 per group
in the EORTC QLQ-C30, and of around 70 in the SF-36
questionnaire, is needed. [68, 69] Second, ten studies
[31, 32, 34, 35, 38–43] were prone to confounding, as
they were observational studies. In these observational
studies, control for potential confounding was per-
formed to varying degrees by only half of the studies [31,
34, 39, 42, 43]. Age, stage, comorbidity and other factors
are strongly associated with HRQoL and with interven-
tion decision. Thus, observational studies should care-
fully account for potential confounding by these factors.
Third, most studies did not assess the results’ clinical
significance [34, 36–38, 40–43], which limits clinical
relevance. Finally, selection bias may occur if patients
experiencing PC recurrence are excluded from sample
analysis. Only two studies explicitly stated whether sur-
vivors with recurrent disease were included in the ana-
lysis, or not.
The strong heterogeneity across studies, and their po-
tential limitations, reveals an urgent need for more high-
quality, large-scale, prospective cohort studies, or RCTs
with repeated follow-up HRQoL assessments.
However, some robust data exist from two RCTs and
one population-based observational, retrospective cohort
study comparing HRQoL by primary intervention in
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survivors with localized stage PC. The data do not sug-
gest HRQoL differs by intervention. However, these
three studies had different comparisons and included, in
total, four different interventions, whereas pooling of
study findings was not possible.
No consistent results could be seen in other studies
based on survivors with locally advanced PC, or on
combining localized or locally advanced PC stage.
Intervention detriments are seen for various scales: (1)
physical well-being, (2) social and role function, (3) vital-
ity and (4) role emotional. However, results are contrac-
tionary due to the previously discussed limitations and
the heterogeneity of included studies. Therefore, the
question of whether HRQoL varies by primary interven-
tion and (if yes), which intervention options are superior
with respect to HRQoL, cannot be answered based on
these studies.
Further, our systematic review has some of its own limita-
tions. As the aim was to compare the influence of primary
interventions on HRQoL in long-term PC survivors, all stud-
ies that did not have a comparison group (either general
population or another intervention group) were excluded
from the review. Additionally, qualitative studies were not in-
cluded as we only wanted to review and compare quantita-
tive studies using validated questionnaires. Furthermore, as
consensus exists that HRQoL is a multidimensional concept
that encompasses all aspects of survivors’ well-being, three
studies that reported or assessed HRQoL on only one do-
main were not included. Additionally, due to the limitations
and variations of the instruments, and comparison groups of
the included studies, result pooling was not possible for the
observational studies, or for the RCTs.
Conclusion
Despite an increasing number of publications studying
HRQoL and/or disease specific symptoms in PC sur-
vivors, only a limited number of publications is avail-
able focusing on long-term PC survivors and primary
intervention. This systematic review exposes the het-
erogeneity of PC intervention studies in terms of (1)
stage at diagnosis, (2) intervention groups and (3) in-
struments used. In addition, most studies are limited
by low sample size, and in the case of observational
studies, potential confounding by indication, or due
to insufficient adjustment.
Robust data from two RCTs and one observational
study, comparing HRQoL by primary intervention in
localized PC survivors, suggest that HRQoL does not
seem to differ by intervention. However, data from
observational studies assessing HRQoL by primary
intervention of PC survivors and combining localized,
or locally advanced stage PC, identified differences for
various scales: physical well-being, social and role
function, vitality and role emotional. However, study
heterogeneity and limitations prevent the identifica-
tion of clear patterns.
Therefore, a review of the existing studies reveals
an urgent need for more high-quality, large-scale,
prospective cohorts or RCTs with repeated follow-up
HRQoL assessments in order to provide clinicians
and patients with sound evidence. Currently, it is
unclear whether HRQoL varies by primary interven-
tion and (if yes) which primary intervention is super-
ior with respect to long-term HRQoL in PC patients.
Additionally, studies should indicate clinical meaning-
fulness in addition to statistically significant differ-
ences, in order to better inform patient/caregiver
decision-making.
Additionally, when HRQoL is assessed, domains other
than physical well-being and PC specific problems (e.g.
incontinence or impotence) should be addressed, as dif-
ferences occurred in various scales.
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